Filgotinib (Jyseleca) Overseas Guide: JAK1 Inhibitor for Rheumatoid Arthritis and Ulcerative Colitis

　　1.Overview and Indications

　　Filgotinib is an oral selective JAK1 inhibitor that reduces inflammatory cytokine signaling by blocking the Janus kinase 1 pathway.Marketed overseas as Jyseleca,it is approved for two main indications:

　　Moderate-to-severe rheumatoid arthritis(RA)in adults:For patients with inadequate response or intolerance to prior DMARDs,it can be used as monotherapy or in combination with methotrexate.

　　Moderate-to-severe active ulcerative colitis(UC)in adults:For patients who have inadequate response,loss of response,or intolerance to conventional therapy or biologics.

　　2.Mechanism and Clinical Value

　　By selectively inhibiting JAK1,filgotinib blocks signaling of pro-inflammatory cytokines such as interferon-gamma,IL-6,and IL-23,thereby reducing inflammation.While its selectivity may offer some safety advantages over pan-JAK inhibitors,its overall safety profile remains similar to other JAK inhibitors.

　　3.Safety Profile and Infection Risk

　　Infections are the most important safety concern.Common adverse events include upper respiratory tract infection,urinary tract infection,nausea,dizziness,and lymphopenia.Some patients may experience serious infections such as shingles or pneumonia.Regular blood count monitoring is recommended,and patients should seek medical attention for persistent fever,significant fatigue,or signs of infection.

　　4.Long-Term Use and Special Population Warnings

　　Overseas regulators have highlighted long-term safety risks of JAK inhibitors,including serious infections,venous thromboembolism(VTE),major adverse cardiovascular events(MACE),and malignancies.Caution is advised in:

　　Adults aged 65 years and older

　　Patients with a history of cardiovascular disease or risk factors

　　Long-term smokers

　　Individuals with risk factors for malignancies

　　5.Real-World Evidence and Conclusion

　　Ongoing real-world safety studies of filgotinib in ulcerative colitis are further evaluating long-term use.Overall,filgotinib provides a targeted treatment option for inflammatory diseases,but requires careful patient selection,infection prevention,and regular monitoring under physician supervision.